Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Cereno Scientific AB (publ) (4A1.F)

0.7420
+0.0150
+(2.06%)
At close: April 25 at 8:48:10 PM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cost of Revenue
-86,746.7020
-80,902.9880
-49,276.6460
-57,538.0690
-44,805.3610
Gross Profit
86,746.7020
80,902.9880
49,276.6460
57,538.0690
44,805.3610
Operating Expense
153,335.1940
156,739.1480
93,926.7050
84,133.9980
59,585.6280
Operating Income
-66,588.4920
-75,836.1600
-44,650.0590
-26,595.9290
-14,780.2670
Net Non Operating Interest Income Expense
-14,118.6990
-23,689.5200
-3,456.1510
-149.2960
-1,244.5990
Pretax Income
-81,119.0070
-99,525.6800
-48,106.2100
-27,648.6490
-16,250.6800
Tax Provision
--
--
--
5.8450
4.2100
Net Income Common Stockholders
-81,119.0070
-99,525.6800
-48,106.2100
-27,654.4940
-16,254.8900
Diluted NI Available to Com Stockholders
-81,119.0070
-99,525.6800
-48,106.2100
-27,654.4940
-16,254.8900
Basic EPS
-0.35
--
-0.21
-0.20
-0.15
Diluted EPS
-0.35
--
-0.21
-0.20
-0.15
Basic Average Shares
281,701.8420
--
185,645.0390
137,514.8440
105,261.7820
Diluted Average Shares
309,158.9260
--
228,455.6870
137,514.8440
105,261.7820
Total Operating Income as Reported
-67,000.3090
-75,836.1600
-44,650.0600
-27,499.3530
-15,006.0810
Rent Expense Supplemental
--
--
--
182.3870
177.0380
Total Expenses
66,588.4920
75,836.1600
44,650.0590
26,595.9290
14,780.2670
Net Income from Continuing & Discontinued Operation
-81,119.0070
-99,525.6800
-48,106.2100
-27,654.4940
-16,254.8900
Normalized Income
-81,119.0070
-99,525.6800
-48,106.2100
-27,654.4940
-16,254.8900
Interest Income
1,844.1350
2,397.3670
1,840.9420
309.7780
1.6800
Interest Expense
15,962.8340
26,086.8870
5,297.0930
459.0740
1,246.2790
Net Interest Income
-14,118.6990
-23,689.5200
-3,456.1510
-149.2960
-1,244.5990
EBIT
-65,156.1730
-73,438.7930
-42,809.1170
-27,189.5750
-15,004.4010
EBITDA
-65,060.9390
-73,151.8490
-42,794.8090
-27,175.2670
-14,990.0930
Reconciled Cost of Revenue
-86,746.7020
-80,902.9880
-49,276.6460
-57,538.0690
-44,805.3610
Reconciled Depreciation
95.2340
286.9440
14.3080
14.3080
14.3080
Net Income from Continuing Operation Net Minority Interest
-81,119.0070
-99,525.6800
-48,106.2100
-27,654.4940
-16,254.8900
Normalized EBITDA
-65,060.9390
-73,151.8490
-42,794.8090
-27,175.2670
-14,990.0930
Tax Rate for Calcs
--
--
--
0.0002
0.0002
12/31/2021 - 5/11/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RIPP.CN Digital Commodities Capital Corp.
0.0400
-20.00%
 
ANIK Anika Therapeutics, Inc.
14.43
+0.38%
 
ANIP ANI Pharmaceuticals, Inc.
69.82
+0.26%
 
ELTP Elite Pharmaceuticals, Inc.
0.4200
+0.02%
 
AKBA Akebia Therapeutics, Inc.
2.3800
+4.39%
 
SXTC China SXT Pharmaceuticals, Inc.
2.2900
+44.94%
 
GELS Gelteq Limited
1.9000
-18.10%